Tirzepatide (brand name **Mounjaro**) is a novel, injectable medication used primarily for the treatment of type 2 diabetes and obesity. It is a dual GLP-1 and GIP receptor agonist, meaning it targets both the GLP-1 (glucagon-like peptide-1) and GIP (gastric inhibitory polypeptide) receptors, which are involved in regulating blood sugar levels, appetite, and insulin sensitivity.
By stimulating both receptors, tirzepatide helps lower blood sugar, promote insulin secretion in response to meals, and improve weight loss by reducing appetite and increasing feelings of fullness. The dual action of tirzepatide is considered to be more effective than drugs targeting only the GLP-1 receptor, leading to superior results in both blood sugar control and weight loss.
Tirzepatide is administered once a week via subcutaneous injection and has been shown to produce significant reductions in A1C (a measure of long-term blood sugar control) and body weight in clinical trials. It is still relatively new and is under study for additional uses beyond diabetes and weight management.
